Only qualified healthcare providers may order

Adult-Onset Disease Risk Screening

This test analyzes a participant’s DNA sample for changes in 73 genes (ACMG73) associated with actionable genetic diseases. The term actionable means that changes can be made to medical care that will lower the chance of developing that disease in the future. Most of the 73 genes are associated with either a hereditary form of cardiovascular disease or cancer risk, as well as several other rare genetic diseases.

This test(s) was developed, and performance characteristics were determined by the HudsonAlpha Clinical Services Lab, LLC. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. These tests are used for clinical purposes, and therefore validation was done as required under the requirements of the Clinical Laboratory Improvement Act (CLIA) of 1988. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The chance of a false negative or a false-positive result due to laboratory error cannot be completely excluded. These results should not be regarded as investigational or for research.